Dendritic cell subsets and type I interferon system in Behçet's disease: Does functional abnormality in plasmacytoid dendritic cells contribute to Th1 polarization?

Clinical and Experimental Rheumatology

Volumn 25, Issue 4 SUPPL. 45, 2007, Pages

  Pay, Salih ^a   Simsek, Ismail ^a   Erdem, Hakan ^a   Pekel, Aysel ^a   Musabak, Ugur ^a   Sengul, Ali ^a   Dinc, Ayhan ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Beh et's disease; Dendritic cell; Interferon; Th1 polarization

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; BETA INTERFERON; CHEMOKINE RECEPTOR CCR7; COLCHICINE; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTICLE; BEHCET DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; MALE; PATHOGENICITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SPONDYLOARTHROPATHY; TH1 CELL; CELL MATURATION; CLINICAL FEATURE; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD DENDRITIC CELL; PLASMACYTOID DENDRITIC CELL; POLARIZATION; PROTEIN BLOOD LEVEL; SPONDYLARTHRITIS; UNDIFFERENTIATED SPONDYLARTHRITIS;

ADULT; BEHCET SYNDROME; CASE-CONTROL STUDIES; CELL COMMUNICATION; DENDRITIC CELLS; FEMALE; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; MALE; SPONDYLARTHRITIS; TH1 CELLS;

EID: 35448996574     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. YAZICI H: BehA̧et's syndrome: an update. Curr Rheumatol Rep 2003; 5: 195-9. Review.
2. DIRESKENELI H: Autoimmunity vs. autoinflammation in Behçet's disease: do we oversimplify a complex disorder? Rheumatology (Oxford) 2006; [Epub ahead of print].
3. SAYINALP N, OZCEBE OI, OZDEMIR O, HAZNEDAROGLU IC, DUNDAR S, KIRAZLI S: Cytokines in Behçet's disease. J Rheumatol 1996; 23: 321-2.
4. BACON TH, OZBAKIR F, ELMS CA, DENMAN AM: Interferon-gamma production by peripheral blood mononuclear cells from patients with Behçet's syndrome. Clin Exp Immunol 1984; 57: 541-7.
5. SAYINALP N, OZCEBE OI, OZDEMIR O, HAZNEDAROGLU IC, DUNDAR S, KIRAZLI S: Cytokines in Behçet's disease. J Rheumatol 1996; 23: 321-2.
6. MEGE JL, DILSEN N, SANGUEDOLCE V et al.: Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20: 1544-9.
7. FRASSANITO MA, DAMMACCO R, CAFFORIO P, DAMMACCO F: Th1 polarization of the immune response in Behçet's disease: A putative pathogenetic role of interleulkin-12. Arthritis Rheum 1999; 42: 1967-74.
8. MELIKOGLU M, UYSAL S, KRUEGER JG et al.: Characterization of the divergent wound-healing responses occurring in the pathergy reaction and normal healthy volunteers. J Immunol 2006; 177: 6415-21.
9. BEN AHMED M, HOUMAN H, MILED M, DELLAGI K, LOUZIR H: Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet's disease. Arthritis Rheum 2004; 50: 2291-5.
10. KAPSENBERG ML: Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 2003; 3: 984-93.
11. DRAKESMITH H, CHAIN B, BEVERLEY P: How can dendritic cells cause autoimmune disease? Immunol Today 2000; 21: 214-7.
12. LEBRE MC, BURWELL T, VIEIRA PL et al.: Differential expression of inflammatory chemokines by Th1- and Th2-cell promoting dendritic cells: a role for different mature dendritic cell populations in attracting appropriate effector cells to peripheral sites of inflammation. Immunol Cell Biol 2005; 83: 525-35.
13. MUSABAK U, PAY S, ERDEM H et al.: Serum interleukin-18 levels in patients with Behçet's disease. Is its expression associated with disease activity or clinical presentations? Rheumatol Int 2006; 26: 545-50.
14. HAMZAOUI A, GHRAIRI H, AMMAR J, ZEKRI S, GUEMIRA F, HAMZAOUI K: IL-18 mRNA expression and IFN-gamma induction in bronchoalveolar lavage from Behçet's disease. Clin Exp Rheumatol 2003; 21(Suppl. 30): S8-14.
15. KAHAN A, HAMZAOUI K, AYED K: Abnormalities of T lymphocyte subsets in Behçet's disease demonstrated with anti-CD45RA and anti-CD29 monoclonal antibodies. J Rheumatol 1992; 19: 742-6.
16. GÜL A: Behçet's disease: an update on the pathogenesis. Clin Exp Rheumatol 2001; 19(Suppl. 24): S6-12.
17. LI B, YANG P, ZHOU H et al.: T-bet expression is upregulated in active Behçet's disease. Br J Ophthalmol. 2003; 87: 1264-7.
18. INTERNATIONAL STUDY GROUP FOR BEHÇET'S DISEASE: Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 1078-80.
19. BHAKTA BB, BRENNAN P, JAMES TE, CHAMBERLAIN MA, NOBLE BA, SILMAN AJ: Behçet's disease: Evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 1999; 38: 728-33.
20. THEOFILOPOULOS AN, BACCALA R, BEUTLER B, KONO DH: Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005; 23: 307-36.
21. RONNBLOM L, ALM GV: Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther 2003; 5: 68-75.
22. KÖTTER I, KOCH S, VONTHEIN R et al.: Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behçet's disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature. Clin Exp Rheumatol 2005; 23(Suppl. 38): S20-6.
23. PESTKA S, KRAUSE CD, WALTER MR: Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202: 8-32.
24. FITZGERALD-BOCARSLY P: Human natural interferon-alpha producing cells. Pharmacol Ther 1993; 60: 39-62.
25. SUZUKI KUROKAWA M, SUZUKI N: Behçet's disease. Clin Exp Med 2004; 4: 10-20. Review.
26. VALLIN H, PERERS A, ALM GV, RONNBLOM L: Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol 1999; 163: 6306-13.
27. SINIGAGLIA F, D'AMBROSIO D, ROGGE L: Type I interferons and the Th1/Th2 paradigm. Dev Comp Immunol 1999; 23: 657-63.
28. KÖTTER I, GUNAYDIN I, ZIERHUT M, STUBIGER N: The use of interferon alpha in Behçet disease: Review of the literature. Semin Arthritis Rheum 2004; 33: 320-35.
29. ANN MARRIE R, RUDICK RA: Drug Insight: interferon treatment in multiple sclerosis. Nat Clin Pract Neurol 2006; 2: 34-44.
30. McFARLAND HF, GOODMAN A, JACOBSON S: Virus-specific cytotoxic T cells in multiple sclerosis. Ann N Y Acad Sci 1988; 532: 273-9.
31. HUSSIEN Y, SANNAA, SODERSTROM M, LINK H, HUANG YM: Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. J Neuroimmunol 2001; 121: 102-10.
32. HUANG YM, ADIKARI S, BAVE U, SANNA A, ALM G: Multiple sclerosis: interferon-beta induces CD123(+)BDCA2- dendritic cells that produce IL-6 and IL-10 and have no enhanced type I interferon production. J Neuroimmunol 2005; 158: 204-12.